MedPath

Loyal Launches Clinical Study for LOY-002, Aiming to Extend Lifespan in Senior Dogs

• Loyal has initiated a clinical study named STAY to evaluate LOY-002, a drug designed to extend lifespan and enhance the quality of life for senior dogs. • The STAY study plans to enroll 1,000 senior dogs across 70 veterinary clinics in the United States, encompassing dogs of nearly all sizes. • LOY-002 represents a significant effort to address aging and improve healthspan in canines, potentially transforming veterinary care for older dogs.

Loyal, a company focused on extending the healthy lifespan of dogs, has announced the launch of a major clinical study, STAY, for its drug candidate LOY-002. The study aims to evaluate the efficacy of LOY-002 in extending lifespan and maintaining quality of life in senior dogs.
The STAY study is set to enroll 1,000 senior dogs of nearly all sizes across 70 veterinary clinics throughout the United States. This large-scale trial underscores Loyal's commitment to rigorous scientific evaluation of its therapies.
LOY-002 represents a novel approach to addressing aging in canines, with the goal of not only extending life but also improving the overall well-being of senior dogs. Further details about the mechanism of action and specific endpoints of the study were not disclosed in the announcement, but the company has indicated that participation details are available on their website.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

NIH Funds Expansion of Dog Aging Project's Rapamycin Trial to Extend Canine Lifespan

The Dog Aging Project (DAP) receives a $7 million NIH grant to expand its clinical trial, TRIAD, studying rapamycin's effect on lifespan in dogs.
Previous DAP studies suggest low-dose rapamycin improves cardiac function, cognitive function, and mobility in canines, warranting further investigation.

Loyal's LOY-002 Receives FDA's RXE Acceptance for Canine Lifespan Extension

Loyal's LOY-002, a drug aimed at extending the healthy lifespan of senior dogs, has received acceptance from the FDA for its Reasonable Expectation of Effectiveness (RXE).
The drug targets age-related metabolic dysfunction in dogs aged 10 years and older, weighing at least 14 lbs, with the goal of improving their quality of life.

Loyal's STAY Study: Clinical Trial Aims to Extend Healthy Lifespan in Senior Dogs

Loyal's STAY study is a nationwide clinical trial assessing a novel drug's ability to extend healthy lifespan in senior dogs, potentially delaying age-related metabolic dysfunction.
The double-blind, placebo-controlled trial involves 1,000 dogs and requires daily oral administration of the drug, with all costs covered by Loyal.

Loyal's Loy-002 Shows Promise in Extending Dog Lifespan in Phase 2 Trial

Loyal is conducting a Phase 2 clinical trial of Loy-002, a drug aimed at extending both the length and quality of life for aging dogs.
Early results from the trial indicate improved metabolic health in dogs, including better insulin sensitivity and muscle regulation.

Loyal's Experimental Drug Aims to Extend Dog Lifespan Through Metabolic Health Improvement

Loyal is conducting a clinical trial for an experimental drug designed to slow down the aging process in dogs, potentially extending their lives.
The drug aims to mimic the benefits of calorie restriction by activating similar metabolic pathways without limiting food intake.

Dog Aging Project Seeks Canine Volunteers for Longevity Research

The Dog Aging Project (DAP) is a five-year study aiming to understand aging in dogs, potentially benefiting human health as well.
Researchers seek diverse canine participants, including large breeds, working dogs, and puppies, to study genetic and environmental factors.

Loyal's Anti-Aging Drug for Senior Dogs Enters Clinical Trials, Aims to Extend Healthy Lifespan

Loyal's LOY-002, a novel anti-aging drug targeting metabolic health in senior dogs, has entered clinical trials, potentially extending their healthy lifespan.
The STAY study, involving over 1,000 dogs across 50+ vet clinics, will assess LOY-002's impact on lifespan and quality of life compared to a placebo over four years.

Dog Aging Project Explores Rapamycin to Extend Lifespan and Improve Healthspan

The Dog Aging Project is studying over 44,000 dogs to understand aging and age-related diseases, aiming to improve both canine and human healthspan.
Researchers are investigating rapamycin, a drug known to extend lifespan in lab animals, to see if it can promote healthy aging and longevity in dogs.

LOY-001 Clears FDA Hurdle, Aiming to Extend Lifespan of Large Dog Breeds

LOY-001, an injectable drug by Loyal for Dogs, has received FDA acceptance for its effectiveness in potentially extending the lifespan of large dog breeds.
The drug targets the IGF-1 hormone, which Loyal's research suggests is linked to shorter lifespans in larger dogs compared to smaller breeds.

Loyal's Large-Scale Clinical Trial Aims to Extend Dog Lifespan

Loyal is conducting a clinical trial to evaluate a daily chewable medication aimed at extending the lifespan and improving the quality of life for dogs aged 10 years and older, weighing at least 14 pounds.
The trial spans up to four years, requiring owners to administer the medication daily and complete surveys on their dog's well-being, either at the vet clinic or remotely.

Reference News

[1]
Helping dogs live longer, healthier lives | Loyal
loyal.com · Sep 16, 2021

A new clinical study, STAY, for LOY-002, aims to extend lifespan and maintain quality of life in senior dogs. Enrolling ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy